About teplizumab
Anti-CD3 monoclonal antibody
Used for
- Delays progression from stage 2 to stage 3 type 1 diabetes in eligible adults and children aged 8 years or older.
Usual adult dose
Daily intravenous infusion for 14 days: 65 micrograms/m² on day 1, increasing to 1,030 micrograms/m² from day 5 onward.
Usual dose in children
For children aged 8 years or older: the same 14-day, body-surface-area-based infusion schedule as adults.
Common side effects
- Low white blood cell counts
- Rash
- Headache
- Nausea
Important warnings
- May cause cytokine release syndrome, especially early in treatment.
- Can increase infection risk and lower lymphocyte counts.
- Liver tests and blood counts require monitoring during treatment.
- Vaccination timing may need adjustment before and after treatment.
Pregnancy
Human pregnancy data are limited; potential fetal harm is possible. Avoid use during pregnancy unless clearly needed.
Breastfeeding
It is not known whether teplizumab passes into breast milk; breastfeeding decisions require clinical assessment.
Interactions
- Live vaccines are generally avoided during treatment and for an appropriate period before and afterward.
- Other medicines that suppress the immune system may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.